Author | Louise Gagnon


Risankizumab outperforms ustekinumab in psoriasis trial

October 19, 2017

The IL-23 inhibitor risankizumab was superior to ustekinumab in a phase two trial of adult patients with moderate-to-severe chronic plaque psoriasis, researchers report. (©FreeBirdPhotos/

Earlier diagnosis of psoriatic arthritis will prevent disease progression

July 24, 2017

Psoriatic arthritis can often go undiagnosed in patients with psoriasis, and an earlier diagnosis is critical to prevent the adverse effects of psoriatic arthritis, according to an expert.

Cumulative dosing of isotretinoin should not follow strict range

October 24, 2016

Cumulative dosing of isotretinoin has followed a reference range of 120 to 150 mg/kg, but there is an absence of strong evidence supporting this recommendation, pointing to the need for clinicians to treat their patients to achieve clearance of acne rather than adhere to this range.

Appreciating the role of microbial communities on the skin

September 28, 2016

Microbial colonization in the development of inflammatory conditions and immune-mediated conditions is a hot research topic, and new dermatologic therapies can potentially result from greater understanding of the role of microbial communities on the skin and in the gut.